ReviewCurrent osteoporosis reports2026
Testosterone and Bone Health in Men.
Review in Current osteoporosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo elucidate the association between testosterone and skeletal health in men. In this review, i) we discuss the influence of testosterone on bone metabolism, ii) review population studies demonstrating the relationship between sex steroid concentrations and bone mineral density (BMD) and bone quality, and iii) summarize data from seminal trials of testosterone therapy and its effects on bone density and fracture risk. RECENT
findingsIn population studies, low testosterone (and estradiol) levels in men are associated with reduced bone mass and a higher risk of fracture. Clinical studies of testosterone replacement in men with organic hypogonadism show robust improvement in BMD. To the contrary, clinical trials of testosterone therapy in middle aged and older men with age-related low testosterone have shown modest increases in BMD (mainly vertebral BMD). Results of the TRAVERSE trial unexpectedly showed higher fracture rates in men randomized to testosterone therapy. Testosterone plays an important role in the maintenance of male skeleton. Most studies of testosterone therapy have demonstrated some degree of improvement in BMD, However, considering that testosterone treatment has not demonstrated reduction in fracture rates, we recommend that hypogonadal men who are at high risk for fracture receive treatment with agents that have proven anti-fracture efficacy.
Indexed as
Identifiers
42141303What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.